DOCSLIB.ORG

Screening/Spot/Colour Test of Anti-Depressants

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Journal of Forensic Chemistry and Toxicology17 Volume 2 Number 1, January - June 2016 Review Article DOI: http://dx.doi.org/10.21088/jfct.2454.9363.2116.4 Screening/Spot/Colour Test of Anti-Depressants A.K. Jaiswal*, Kamna Sharma**, Sally Lukose**, T. Millo*, Anu Singla***, Kulbhushan Prasad*, S.K. Gupta* Authors Affiliation: * Department of Forensic Medicine Reprints Requests: A. K. Jaiswal, Chemist, Department and Toxicology, All India Institute of Medical Sciences, New of Forensic Medicine and Toxicology, All India Institute of Delhi- 110029. ** Galgotias University, Greater Noida- Medical Sciences, Ansari Nagar, New Delhi-110 029, New 201306,U.P. ***Institute of Forensic Science & Criminology, Delhi. Bundelkhand University, Jhansi, U.P. E-mail: [email protected] Abstract Antidepressants are class of drugs that reduce symptoms of depressive disorders by correctly chemical imbalances of neurotransmitters in the brain. These imbalances may be responsible for changes in mood and behaviour of an individual. In forensic autopsy case, the forensic pathologist may require a complete toxicological investigation for different poisons including Anti-depressents. In India, Forensic Science Laboratories run by Government under the Home ministry usually carry out this The samples have to be analyzed by the forensic Toxicologist/Chemists/ Scientist. This article deals with the screening/spot test for antidepressants in a step-wise manner, which can be of handy reference for the forensic toxicologist.This article is in continuation of toxicology manual series-XVIII, screening/spot test of aphrodisiacs (sex drugs), International Journal of Medical Toxicology & Legal Medicine,Vol.14, No.3 Jan-March 2012. Keywords: Antidepressants; Screening; Colour; Spot Test etc. Introduction screening/spot test for alkaloids which are easily available and useful for the forensic science laboratory. This article covers the spot test/colour ntidepressants are the drugs that are used to test of anti-depressants such as amitriptyline, Arelieve the symptoms of depression. They butriptyline, clomipramine, desipramine, were first developed in the 1950’s and have been dibenzepin, dosulepin, doxepin, imipramine, used on regular basis. Initially used for the treatment iproniazid, isocarboxazid, mebarazine, mianserin, of depression in addition to improving one’s mood nialamide, nomifensive, nortriptyline, noxiptiline, as well as behaviour. The intake of antidepressants opipramol, phenelzine, protriptylin, tofenacin, enhances the activity of certain chemicals that work trazodone, trimipramine, viloxazine and zimeldin in our brain known as neuro transmitters. They pass etc [3-9]. on the signals from one cell to another. These drugs are advised to the patients suffering from moderate to severe depression illness, severe anxiety, panic Amitriptyline attacks, obsessive compulsive disorders and post Marquis test traumatic stress disorder. They are basically 1. Two ml of extract is taken in test tube. classified on the basis of which chemicals in the brain they affect [1-2]. 2. Few drops of marquis reagent are added to it. We have tried to set out standard procedures for 3. Brown to orange colour is observed which indicates the presence of amitriptyline. Journal© 2016 ofRed Forensic Flower Chemistry Publication and Pvt. Toxicology Ltd. / Volume 2 Number 1 / January - June 2016 18 A.K. Jaiswal et. al. / Screening/Spot/Colour Test of Anti-Depressants Table 1: Classification of antidepressants S. no Types General Information Examples 1. Monoamine oxidase inhibition It is given those individuals who don’t Phenelzine, respond to any other antidepressants. It must tranylcypromine not be taken with certain foods, beverages and medications can cause dangerous interactions. 2. Tricyclic antidepressants TCAs are rapidly absorbed from the Amitryptyline, drugs Digestive tract, bind to plasma proteins, and Imipramine, become widely distributed in tissues as a Clomipramine result of their lipophilic nature. It affects the neurotransmitters norepinephine & serotonin. 3. Selective serotonin reuptake It affects the serotonin levels in the brain. Fluoxetine, Sertraline, inhibitors Serotonin is a chemical neurotransmitters Citalopram used to treat depression. 4. Serotonin & norepinephrin It works on two chemical neurotransmitters Duloxetine, velafaxine reuptake inhibitors serotonin as well as norepinephrin. It is used to treat the major depression as well as mood disorders. 5. Norepinephrin & dopamine It works on increasing the level of Buproprion reuptake inhibitors norepinephrin and dopamine to prevent their reabsorption into the cell. 6. Combined reuptake inhibitors It is useful in two ways firstly it prevents the Trazidone, maprotiline and receptor blockers reabsorption into the nerve cell and at the same time blocking the nerve cell receptors Mandelin’s Test presence of clomipramine. • Two ml of extract is taken in test tube. • Few drops of mandelin’s reagent are added to it. FPN test • Colour changes from brown to green which • Two ml of extract is taken in test tube. indicates the presence of amitriptyline. • Few drops of FPN reagent are added to it. • Blue colour is observed which indicates the Sulphuric Acid Test presence of clomipramine. • Few drops of extract are taken on a white tile. • Few drops of sulphuric acid are added to it. Mandelin’s test • Orange colour is observed which indicates the • Two ml of extract is taken in test tube. presence of amitriptyline. • Few drops of mandelin’s reagent are added to it. • Blue colour is observed which indicates the Butriptyline presence of clomipramine. Marquis test • Two ml of extract is taken in test tube. Libermann’s test • Few drops of marquis reagent are added to it. • One to two ml of extract is taken in test tube. • Violet colour is observed which indicates the • Few drops of libermann’s reagent are added to presence of butriptyline. it. • Blue colour is observed which indicates the Clomipramine presence of clomipramine. Forrest Test Desipramine • One to two ml of extract is taken in test tube. Forrest Test • Few drops of forrest reagent are added to it. • One to two ml of extract is taken in test tube. • Blue colour is observed which indicates the • Few drops of forrest reagent are added to it. Journal of Forensic Chemistry and Toxicology / Volume 2 Number 1 / January - June 2016 A.K. Jaiswal et. al. / Screening/Spot/Colour Test of Anti-Depressants 19 • Blue colour is observed which indicates the • Few drops of libermann’s reagent are added to it. presence of desipramine. • Black colour is observed which indicates the presence of doxepin. Mandelin’s Test • Two ml of extract is taken in test tube. Mandelin’s Test • Few drops of mandelin’s reagent are added to it. • Two ml of extract is taken in test tube. • Colour changes from yellow to blue which • Few drops of mandelin’s reagent are added to it. indicates the presence of desipramine. • Brown colour is observed which indicates the presence of doxepin. Dibenzepin Mandelin’s Test Marquis Test • Two ml of extract is taken in test tube. • Two ml of extract is taken in test tube. • Few drops of mandelin’s reagent are added to it. • Few drops of marquis reagent are added to it. • Green colour is observed which indicates the • Brown colour is observed which indicates the presence of dibenzepin. presence of doxepin. Dosulepin Sulphuric Acid Test Libermann’s Test • Few drops of extract are taken on a white tile. • One to two ml of extract is taken in test tube. • Few drops of sulphuric acid are added to it. • Few drops of libermann’s reagent are added to it. • Orange colour is observed which indicates the • Reddish brown colour is observed which presence of doxepin. indicates the presence of dosulepin. Imipramine Mandelin’s Test Forrest Test • Two ml of extract is taken in test tube. • One to two ml of extract is taken in test tube. • Few drops of mandelin’s reagent are added to it. • Few drops of forrest reagent are added to it. • Green colour is observed which indicates the • Blue colour is observed which indicates the presence of dosulepin. presence of imipramine. Marquis Test FPN Test • Two ml of extract is taken in test tube. • One to two ml of extract is taken in test tube. • Few drops of marquis reagent are added to it. • Few drops of FPN reagent are added to it. • Brown colour is observed which indicates the presence of dosulepin. • Blue colour is observed which indicates the presence of imipramine. Sulphuric Acid Test • Few drops of extract are taken on a spotting tile. Mandelin’s Test • Few drops of sulphuric acid are added to it. • Two ml of extract is taken in test tube. • Violet colour is observed which indicates the • Few drops of mandelin’s reagent are added to it. presence of dosulepin. • Blue colour is observed which indicates the presence of imipramine. Doxepin Libermann’s test Libermann’s Test • One to two ml of extract is taken in test tube. • One to two ml of extract is taken in test tube. Journal of Forensic Chemistry and Toxicology / Volume 2 Number 1 / January - June 2016 20 A.K. Jaiswal et. al. / Screening/Spot/Colour Test of Anti-Depressants • Few drops of libermann’s reagent are added to to it. it. • Above solution is heated for two minutes. • Blue colour is observed which indicates the • Black colour is observed which indicates the presence of imipramine. presence of mebarazine. Iproniazid Sulphuric Acid Test Cyanogen Bromide Test • Few drops of extract are taken on a white tile. • One to two ml of extract is taken in test tube. • Few drops of sulphuric acid are added to it. • Few drops of cyanogens bromide reagent are • Orange colour is observed which indicates the added to it. presence of mebarazine. • Orange to pink colour is observed which indicates the presence of iproniazid. Mianserin Mandelin’s Test Nessler’s Test • Two ml of extract is taken in test tube. • Two to three drops of extract is taken in a • porcelain basin. Few drops of mandelin’s reagent are added to it.
Recommended publications
  • Fatal Toxicity of Antidepressant Drugs in Overdose

    Fatal Toxicity of Antidepressant Drugs in Overdose

    BRITISH MEDICAL JOURNAL VOLUME 295 24 OCTOBER 1987 1021 Br Med J (Clin Res Ed): first published as 10.1136/bmj.295.6605.1021 on 24 October 1987. Downloaded from PAPERS AND SHORT REPORTS Fatal toxicity of antidepressant drugs in overdose SIMON CASSIDY, JOHN HENRY Abstract dangerous in overdose, thus meriting investigation of their toxic properties and closer consideration of the circumstances in which A fatal toxicity index (deaths per million National Health Service they are prescribed. Recommendations may thus be made that prescriptions) was calculated for antidepressant drugs on sale might reduce the number offatalities. during the years 1975-84 in England, Wales, and Scotland. The We used national mortality statistics and prescription data tricyclic drugs introduced before 1970 had a higher index than the to compile fatal toxicity indices for the currently available anti- mean for all the drugs studied (p<0-001). In this group the depressant drugs to assess the comparative safety of the different toxicity ofamitriptyline, dibenzepin, desipramine, and dothiepin antidepressant drugs from an epidemiological standpoint. Owing to was significantly higher, while that ofclomipramine, imipramine, the nature of the disease these drugs are particularly likely to be iprindole, protriptyline, and trimipramine was lower. The mono- taken in overdose and often cause death. amine oxidase inhibitors had intermediate toxicity, and the antidepressants introduced since 1973, considered as a group, had significantly lower toxicity than the mean (p<0-001). Ofthese newer drugs, maprotiline had a fatal toxicity index similar to that Sources ofinformation and methods of the older tricyclic antidepressants, while the other newly The statistical sources used list drugs under their generic and proprietary http://www.bmj.com/ introduced drugs had lower toxicity indices, with those for names.
  • 1 Supplemental Figure 1: Illustration of Time-Varying

    1 Supplemental Figure 1: Illustration of Time-Varying

    Supplemental Material Table of Contents Supplemental Table 1: List of classes and medications. Supplemental Table 2: Association between benzodiazepines and mortality in patients initiating hemodialysis (n=69,368) between 2013‐2014 stratified by age, sex, race, and opioid co‐dispensing. Supplemental Figure 1: Illustration of time‐varying exposure to benzodiazepine or opioid claims for one person. Several sensitivity analyses were performed wherein person‐day exposure was extended to +7 days, +14 days, and +28 days beyond the outlined periods above. 1 Supplemental Table 1: List of classes and medications. Class Medications Short‐acting benzodiazepines Alprazolam, estazolam, lorazepam, midazolam, oxazepam, temazepam, and triazolam Long‐acting benzodiazepines chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam Opioids alfentanil, buprenorphine, butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphine, meperidine, methadone, morphine, nalbuphine, nucynta, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, tapentadol, talwin, tramadol, carfentanil, pethidine, and etorphine Antidepressants citalopram, escitalopram, fluoxetine, fluvozamine, paroxetine, sertraline; desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine; vilazodone, vortioxetine; nefazodone, trazodone; atomoxetine, reboxetine, teniloxazine, viloxazine; bupropion; amitriptyline, amitriptylinoxide, clomipramine, desipramine, dibenzepin, dimetacrine, dosulepin, doxepin, imipramine, lofepramine, melitracen,
  • Tricyclic Antidepressants Versus

    Tricyclic Antidepressants Versus

    Jørgensen et al. Syst Rev (2021) 10:227 https://doi.org/10.1186/s13643-021-01789-0 PROTOCOL Open Access Tricyclic antidepressants versus ‘active placebo’, placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis Caroline Kamp Jørgensen1* , Sophie Juul1,2,3, Faiza Siddiqui1, Marija Barbateskovic1, Klaus Munkholm4, Michael Pascal Hengartner5, Irving Kirsch6, Christian Gluud1 and Janus Christian Jakobsen1,7 Abstract Background: Major depressive disorder is a common psychiatric disorder causing great burden on patients and societies. Tricyclic antidepressants are frequently used worldwide to treat patients with major depressive disorder. It has repeatedly been shown that tricyclic antidepressants reduce depressive symptoms with a statistically signifcant efect, but the efect is small and of questionable clinical importance. Moreover, the benefcial and harmful efects of all types of tricyclic antidepressants have not previously been systematically assessed. Therefore, we aim to investigate the benefcial and harmful efects of tricyclic antidepressants versus ‘active placebo’, placebo or no intervention for adults with major depressive disorder. Methods: This is a protocol for a systematic review with meta-analysis that will be reported as recommended by Pre- ferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols, bias will be assessed with the Cochrane Risk of Bias tool—version 2, our eight-step procedure will be used to assess if the thresholds for clinical signifcance are crossed, Trial Sequential Analysis will be conducted to control random errors and the certainty of the evidence will be assessed with the Grading of Recommendations Assessment, Development and Evaluation approach.
  • Effect of Depression and Diabetes Mellitus on the Risk for Dementia: a National Population-Based Cohort Study

    Effect of Depression and Diabetes Mellitus on the Risk for Dementia: a National Population-Based Cohort Study

    Supplementary Online Content Katon W, Pedersen HS, Ribe AR, et al. Effect of depression and diabetes mellitus on the risk for dementia: a national population-based cohort study. JAMA Psychiatry. Published online April 15, 2015. doi:10.1001/jamapsychiatry.2015.0082. eAppendix 1. Information on Depression Obtained From the Danish Psychiatric Central Research Register and the Danish National Prescription Registry eAppendix 2. Information on Severe Mental Illness Obtained From the Danish Psychiatric Central Research Register eAppendix 3. Information on Diabetes Mellitus Obtained From the Danish National Diabetes Register eAppendix 4. Information on Dementia Obtained From the Danish Psychiatric Central Research Register, the Danish National Patient Register, and the Danish National Prescription Registry eAppendix 5. Information on Marital Status Obtained From the Danish Civil Registration System eAppendix 6. Information on Chronic Diseases and Diabetic Complications Obtained From the Danish National Patient Register This supplementary material has been provided by the authors to give readers additional information about their work. © 2015 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/23/2021 eAppendix 1. Information on depression obtained from the Danish Psychiatric Central Research Register and the Danish National Prescription Registry A diagnosis of depression was identified if at least one of the following criteria applied: 1. Registration of a diagnosis of depression in the Danish
  • CCDAN Search Strategies (All Antidepressants)

    CCDAN Search Strategies (All Antidepressants)

    CCDAN search strategies (all antidepressants) 1. Cochrane Depression, Anxiety and Neurosis Review Group’s Specialized Register (CCDANCTR) #1 (antidepress* or anti-depress* or "anti depress*" or MAOI* or RIMA* or “monoamine oxidase inhibit*” or ((serotonin or norepinephrine or noradrenaline or neurotransmitter* or dopamin*) NEAR (uptake or reuptake or re-uptake or "re uptake")) or SSRI* or SNRI* or NARI* or SARI* or NDRI* or TCA* or tricyclic* or tetracyclic* or pharmacotherap* or psychotropic* or "drug therapy") #2 (Agomelatine or Alaproclate or Amoxapine or Amineptine or Amitriptylin* or Amitriptylinoxide or Atomoxetine or Befloxatone or Benactyzine or Binospirone or Brofaromine or (Buproprion or Amfebutamone) or Butriptyline or Caroxazone or Cianopramine or Cilobamine or Cimoxatone or Citalopram or (Chlorimipramin* or Clomipramin* or Chlomipramin* or Clomipramine) or Clorgyline or Clovoxamine or (CX157 or Tyrima) or Demexiptiline or Deprenyl or (Desipramine* or Pertofrane) or Desvenlafaxine or Dibenzepin or Diclofensine or Dimetacrin* or Dosulepin or Dothiepin or Doxepin or Duloxetine or Desvenlafaxine or DVS-233 or Escitalopram or Etoperidone or Femoxetine or Fluotracen or Fluoxetine or Fluvoxamine or (Hyperforin or Hypericum or “St John*”) or Imipramin* or Iprindole or Iproniazid* or Ipsapirone or Isocarboxazid* or Levomilnacipran or Lofepramine* or (“Lu AA21004” or Vortioxetine) or "Lu AA24530" or (LY2216684 or Edivoxetine) or Maprotiline or Melitracen or Metapramine or Mianserin or Milnacipran or Minaprine or Mirtazapine or Moclobemide
  • Antidepressants for Insomnia in Adults (Review)

    Antidepressants for Insomnia in Adults (Review)

    Cochrane Database of Systematic Reviews Antidepressants for insomnia in adults (Review) Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, Manson CCF, Wilson S Everitt H, Baldwin DS, Stuart B, Lipinska G, Mayers A, Malizia AL, Manson CCF, Wilson S. Antidepressants for insomnia in adults. Cochrane Database of Systematic Reviews 2018, Issue 5. Art. No.: CD010753. DOI: 10.1002/14651858.CD010753.pub2. www.cochranelibrary.com Antidepressants for insomnia in adults (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 6 OBJECTIVES ..................................... 8 METHODS ...................................... 8 Figure1. ..................................... 10 RESULTS....................................... 12 Figure2. ..................................... 14 Figure3. ..................................... 15 Figure4. ..................................... 24 ADDITIONALSUMMARYOFFINDINGS . 27 DISCUSSION ..................................... 32 AUTHORS’CONCLUSIONS . 35 ACKNOWLEDGEMENTS . 35 REFERENCES ..................................... 36 CHARACTERISTICSOFSTUDIES . 41 DATAANDANALYSES. 95 Analysis 1.1. Comparison 1 Selective serotonin reuptake inhibitors (SSRI) versus other antidepressants, Outcome 1 Subjective measure of sleep quality. ...... 96
  • Antidepressant” a Review of the Evidence for on and Off Label Uses

    Antidepressant” a Review of the Evidence for on and Off Label Uses

    9/25/2020 The Versatile “Antidepressant” A review of the evidence for on and off label uses Mark Aksamit MPAS, PA-C, PSY-CAQ Kelly Gassman MPAS, PA-C 1 Introductions • Mark Aksamit – Nothing to disclose • Assistant Professor UNMC PA Program • Co-Director Psychiatry Department Treatment Resistant Depression Subspecialty • Transplant Psychiatry • Kelly Gassman – Nothing to disclose • Addiction Psychiatry Subspecialty • Treatment Resistant Depression Subspecialty 2 1 9/25/2020 Objectives • Describe the hypothesized roles of specific neurotransmitters and receptors (antidepressants) in treating various psychiatric and medical conditions. • Explain hypothesized mechanisms of action for various psychotropic medications. • Evaluate the evidence for on and off-label usage of various psychotropic medications within the context of medical comorbidity. 3 Overview Today’s Topics 1. Introduction to “antidepressants” 2. Proposed MOAs of various antidepressants 3. Different conditions antidepressants are proposed to help with 4. Review of evidence for & against complementary use in comorbid conditions 4 2 9/25/2020 “Antidepressants” • Commonly known to help with various psychiatric conditions • What is depression? • Polypharmacy a growing problem 5 SSRIs & SNRIs Selective Serotonin Serotonin-Norepinephrine Reuptake Inhibitors Reuptake Inhibitors Citalopram Desvenlafaxine Escitalopram Duloxetine Fluoxetine Levomilnacipran Fluvoxamine Milnacipran Venlafaxine Paroxetine Sertraline 6 3 9/25/2020 TCAs Tricyclic Antidepressants • Amitriptyline • Lofepramine
  • UPDATE on NEURO/PSYCH MEDICATIONS Steve Williams, Pharm.D

    UPDATE on NEURO/PSYCH MEDICATIONS Steve Williams, Pharm.D

    UPDATE ON NEURO/PSYCH MEDICATIONS Steve Williams, Pharm.D. - clinical pharmacist, clinical professor DEMENTIA Type of % of Symptoms Pathology Dementia Dementias Alzheimer’s Memory: names, recent Atrophy 55 events, language generalized, deficits (aphasia, esp. apraxia), Late: temporal, pit. mood/aggression Lewy Body Visual hallucinations, Atrophy, 20 cognition fluctuation Lewy bodies Parkinsonian: gait, cortex tremor, rigid tone, falls – sensitive to antipsychotics, PD meds Vascular Focal signs, stepwise Stroke, 15 decline diabetes Pseudo Mimics dementia Depression, * bipolar, Other Nutritional, trauma, Fe, B12, 10 AIDS, thyroid, folate, drugs/alcohol ADUCANUMAB • Sept 1 2016 Nature • MAB targeting amyloid plaque • Scientists may have ‘game changer’ drug to treat Alzheimer’s Type of % of Symptoms Pathology Dementia Dementias Alzheimer’s Memory: names, recent Atrophy 55 events, language generalized, deficits, aphasia, esp. apraxia, Late: temporal, pit. mood/aggression Lewy Body Visual hallucinations, Atrophy, 20 cognition fluctuation Lewy bodies Parkinsonian: gait, cortex tremor, rigid tone, falls – sensitive to antipsychotics, PD meds Vascular Focal signs, stepwise Stroke, 15 decline diabetes Pseudo Mimics dementia Depression, * bipolar, Other Nutritional, trauma, Fe, B12, 10 AIDS, thyroid, folate, drugs/alcohol NUPLAZID (PIMAVANSERIN) • Parkinson’s Disease - Psychosis • Caused by low dopamine • Medications increasing dopamine can cause hallucinations • Clozapine and Quetiapine used – mechanism is serotonin (5-HT2A) receptor blockade •
  • The Problem of Tricyclic Antidepressant Poisoning PETER CROME BELINDA NEWMAN M.B., M.R.C.P

    The Problem of Tricyclic Antidepressant Poisoning PETER CROME BELINDA NEWMAN M.B., M.R.C.P

    Postgrad Med J: first published as 10.1136/pgmj.55.646.528 on 1 September 1979. Downloaded from Postgraduate Medical Jouirnal (August 1979) 55, 528-532 The problem of tricyclic antidepressant poisoning PETER CROME BELINDA NEWMAN M.B., M.R.C.P. B.A., M.Sc. Poisons Unit, Guy's Hospital, London SE] 9RT Summary Edinburgh Poisons Treatment Centre. Their con- In the year May 1976 to April 1977, 489 enquiries clusions were that most of these patients were not about the management of tricyclic antidepressant severely affected and that recovery was usually poisoning received at the London Centre of the Nat- rapid and uneventful, supportive treatment being all ional Poisons Information Service were followed-up. that was necessary. In their study no patients re- One hundred and sixty-four patients (33-5%) were quired artificial ventilation and there were no deaths. unconscious, convulsions occurred in 62 (12-7y/), hy- It seemed possible to the present authors that those potension in 31 (6-3%), respiratory depression in 28 findings no longer held true, for since then both the (5-70%), tachydysrhythmias in 17 (3-5%) and cardiac number of different antidepressants and the number arrest in 12 patients (2-5%). Sixteen patients died of admissions to hospital have increased. Support (3.30%). No statistically significant differences were for this view comes in a study from the same unitProtected by copyright. found between individual antidepressants although which reported that the proportion of patients poisoning with amitriptyline-like drugs resulted in a admitted with poisoning from these drugs who were significantly higher proportion of unconscious patients in Grade IV coma had increased from 3-90 in the than poisoning with imipramine-like drugs (P< 0-01).
  • Antidepressants and Movement Disorders

    Antidepressants and Movement Disorders

    Revet et al. BMC Psychiatry (2020) 20:308 https://doi.org/10.1186/s12888-020-02711-z RESEARCH ARTICLE Open Access Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database Alexis Revet1,2,3* , François Montastruc1,2,4, Anne Roussin1,2,4, Jean-Philippe Raynaud2,3, Maryse Lapeyre-Mestre1,2,4 and Thi Thu Ha Nguyen1,2 Abstract Background: Antidepressants-induced movement disorders are rare and imperfectly known adverse drug reactions. The risk may differ between different antidepressants and antidepressants’ classes. The objective of this study was to assess the putative association of each antidepressant and antidepressants’ classes with movement disorders. Methods: Using VigiBase®, the WHO Pharmacovigilance database, disproportionality of movement disorders’ reporting was assessed among adverse drug reactions related to any antidepressant, from January 1967 to February 2017, through a case/non-case design. The association between nine subtypes of movement disorders (akathisia, bruxism, dystonia, myoclonus, parkinsonism, restless legs syndrome, tardive dyskinesia, tics, tremor) and antidepressants was estimated through the calculation first of crude Reporting Odds Ratio (ROR), then adjusted ROR on four potential confounding factors: age, sex, drugs described as able to induce movement disorders, and drugs used to treat movement disorders. Results: Out of the 14,270,446 reports included in VigiBase®, 1,027,405 (7.2%) contained at least one antidepressant, among whom 29,253 (2.8%) reported movement disorders. The female/male sex ratio was 2.15 and the mean age 50.9 ± 18.0 years. We found a significant increased ROR for antidepressants in general for all subtypes of movement disorders, with the highest association with bruxism (ROR 10.37, 95% CI 9.62–11.17) and the lowest with tics (ROR 1.49, 95% CI 1.38–1.60).
  • Appendix & Tables

    Appendix & Tables

    Supplemental materials for: Maund E, Stuart B, Moore M, et al. Managing antidepressant discontinuation: a systematic review. Ann Fam Med. 2019;17(1):52-60. 1 Supplemental APPENDIX 1 - SEARCH STRATEGIES MEDLINE Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to 23 March 2017 Search Query Items ID# found 1 exp ANTIDEPRESSIVE AGENTS/ 133782 2 exp NEUROTRANSMITTER UPTAKE INHIBITORS/ 133192 3 (psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 136112 noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*).ti,kf,hw. 4 (Agomelatine or Alaproclate or Alnespirone or Amoxapine or Amersergide or 44215 Amfebutamone or Amiflamine or Amineptine or Amitriptylin* or Amitriptylinoxide or Amoxapine or Aripiprazole or Atomoxetine or Tomoxetine or Befloxatone or Benactyzine or Binospirone or Brofaromine or Bupropion or Butriptylin*or Caroxazone or Chlopoxiten or Cianopramine or Cilobamine or Cilosamine or Cimoxatone or Citalopram or (Chlorimipramin* or Clomipramin* or Chlomipramin* or Clorimipramine) or Clorgyline or Clovoxamine or Dapoxetine or Deanol or Dibenzepin or Demexiptilin* or Deprenyl or Desipramine or Desvenlafaxine or Dibenzepin or Diclofensin* or Dimetacrin* or (Dosulepin or Dothiepin) or Doxepin or Duloxetine or DVS 233 or Enilospirone or Eptapirone
  • Table [1]: Definition of Reported Outcomes Study Outcome

    Table [1]: Definition of Reported Outcomes Study Outcome

    Table [1]: Definition of reported outcomes Study outcome Definitions Adverse events Treatment side effect Depression severity and Change in depression symptoms from baseline using depression standardized treatment efficacy scale (PHQ-9 ,Beck Depression Inventory (BDI),BDI for primary care, Zung Self-Rating Depression Scale (SDS),Center for Epidemiologic Studies- Depression Scale (CES-D),Center for Epidemiologic Studies-Depression Scale (CES-D), Montgomery-Asberg Depression Rating Scale (MADRS), Minnesota Multiphasic Personality Inventory (MMPI), depression symptoms improvement. Dropout rate Percentage of patients who dropout from each treatment arm. Clinical Response ≥30%depression improvement (from baseline to endpoint). Remission Scores lower than 8 in the HAMD or more than 70% depression improvement. Relapse rate Return of symptoms to the full syndrome criteria for an episode during remission. Table[2]: Characteristics of the systematic reviews Author, year Studies Study Population/ country Interventions Comparison Outcome Alyson 201220 23 RCTs 211 patients / NR Group CBT Control -Depression severity measured by any standardized Scale Almeida 201521 11 RCTs Patients with depression Naturopathic Control -Depression (6 studies symptoms / NR severity measured included into by any our analysis) standardized Scale Amick 201522 11 RCTs Canada, Germany, England, AD CBT - Depression (6 studies Iran, Romania and United States severity measured included into by any our analysis) standardized scale -Response -Remission Arnberg 201423 40 RCTs 260 patients were included CCBT WL -Depression (only three Switzerland, Australia, Sweden severity measured studies were by any included to standardized our analysis) scale Berlim 201424 29 RCTS Subjects aged 18–75 years Biological Control -Response (only 17 with a diagnosis of primary MD/ intervention -Remission rates studies were NR -drop-out included to rates our analysis) Bower 201125 9 RCTS Participants (age 18+) with Psychotherapy -AD -Depression (only three depression.